RHUMBLINE ADVISERS - CATALYST PHARMACEUTICALS INC ownership

CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 192 filers reported holding CATALYST PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.1%.

Quarter-by-quarter ownership
RHUMBLINE ADVISERS ownership history of CATALYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$3,415,629
-11.6%
292,186
+1.6%
0.00%0.0%
Q2 2023$3,864,833
+82925.4%
287,562
+2.4%
0.00%
-33.3%
Q1 2023$4,655
-5.3%
280,781
+6.2%
0.01%
-14.3%
Q4 2022$4,917
-99.9%
264,341
+2.3%
0.01%
+40.0%
Q3 2022$3,314,000
+326.5%
258,301
+133.2%
0.01%
+400.0%
Q2 2022$777,000
-26.8%
110,784
-13.4%
0.00%0.0%
Q1 2022$1,061,000
+5.6%
127,953
-13.8%
0.00%0.0%
Q4 2021$1,005,000
+26.7%
148,483
-0.7%
0.00%0.0%
Q3 2021$793,000
-6.4%
149,572
+1.5%
0.00%0.0%
Q2 2021$847,000
+53.7%
147,391
+23.3%
0.00%0.0%
Q1 2021$551,000
+30.6%
119,546
-5.3%
0.00%0.0%
Q4 2020$422,000
+19.2%
126,286
+6.0%
0.00%0.0%
Q3 2020$354,000
-43.6%
119,156
-12.4%
0.00%0.0%
Q2 2020$628,000
+29.2%
135,961
+7.7%
0.00%0.0%
Q1 2020$486,000
+2.7%
126,260
+0.1%
0.00%0.0%
Q4 2019$473,000
-29.0%
126,145
+0.6%
0.00%0.0%
Q3 2019$666,000
+37.3%
125,392
-0.6%
0.00%0.0%
Q2 2019$485,000
-22.9%
126,182
+2.4%
0.00%0.0%
Q1 2019$629,000
+158.8%
123,245
-2.7%
0.00%0.0%
Q4 2018$243,000
-23.8%
126,699
+49.9%
0.00%0.0%
Q3 2018$319,000
+12.7%
84,500
-6.9%
0.00%0.0%
Q2 2018$283,000
+75.8%
90,725
+34.7%
0.00%
Q1 2018$161,000
-34.0%
67,342
+7.7%
0.00%
Q4 2017$244,000
+25.8%
62,517
-18.6%
0.00%
Q3 2017$194,000
-7.2%
76,796
+1.4%
0.00%
Q2 2017$209,000
+132.2%
75,701
-1.2%
0.00%
Q1 2016$90,000
-51.1%
76,641
+1.9%
0.00%
-100.0%
Q4 2015$184,000
-10.7%
75,216
+9.8%
0.00%0.0%
Q3 2015$206,000
-22.8%
68,506
+5.8%
0.00%0.0%
Q2 2015$267,00064,7650.00%
Other shareholders
CATALYST PHARMACEUTICALS INC shareholders Q2 2022
NameSharesValueWeighting ↓
TANAKA CAPITAL MANAGEMENT INC 148,281$2,4587.14%
GABLES CAPITAL MANAGEMENT INC. 409,080$6,782,5464.74%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 10,355,099$171,687,5413.83%
JW Asset Management, LLC 563,392$9,341,0393.58%
Quantedge Capital Pte Ltd 324,700$5,383,5262.10%
Paradiem, LLC 236,628$3,923,2921.22%
SummerHaven Investment Management, LLC 100,592$1,667,8150.97%
Capital Impact Advisors, LLC 46,096$764,2720.94%
Yorktown Management & Research Co Inc 50,000$829,0000.89%
Seaport Global Advisors, LLC 15,598$258,6150.82%
View complete list of CATALYST PHARMACEUTICALS INC shareholders